Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14282777 | 0.71 | SMN1; SMN2 (0.49) | SMN1; SMN2 | |
| SCHEMBL14318699 | 0.64 | KDM4E (0.41) | IDO1TP53 | |
| SCHEMBL8250249 | 0.60 | PTGS1 (0.57) | NPC1TP53RAB9A | |
| SCHEMBL6336691 | 0.57 | SMN1; SMN2 (0.55) | TSHRSMN1; SMN2 | |
| SCHEMBL10812713 | 0.56 | DCUN1D1 (0.37) | CHRM1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL817554 | 0.55 | ALOX5 (0.65) | PGRNOTUMIDO1NPC1TP53 | |
| SCHEMBL31222672 | 0.55 | ALOX5 (0.65) | PGRNOTUMIDO1NPC1TP53 | |
| SCHEMBL6500333 | 0.55 | P2RX7 (0.44) | IDO1TP53TSHR | |
| SCHEMBL6500326 | 0.55 | P2RX7 (0.44) | IDO1TP53TSHR | |
| SCHEMBL6500321 | 0.55 | P2RX7 (0.44) | IDO1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009622-A1 | METHOD FOR PRODUCING PYRIMIDINE COMPOUND | AJINOMOTO CO., INC. (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009622-A1 | METHOD FOR PRODUCING PYRIMIDINE COMPOUND | TYMS, TYMP, UMPS | PGR 1136/4885GSK3B 4202/4885CHRM1 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.